What are the appropriate admitting orders for a patient with an acute myocardial infarction?

Admitting Orders for Acute Myocardial Infarction

Patients with acute myocardial infarction should be admitted using standardized order sets that incorporate immediate aspirin, dual antiplatelet therapy, anticoagulation, high-intensity statin, ACE inhibitor (when indicated), beta-blocker (when indicated), continuous cardiac monitoring with defibrillator capability, and direct transfer to the cardiac catheterization laboratory for primary PCI—bypassing the emergency department—when feasible within 90–120 minutes of first medical contact. 1

Immediate Actions (First 10 Minutes)

• Obtain a 12-lead ECG within 10 minutes of arrival to confirm ST-segment elevation, new left bundle branch block, or posterior MI patterns 2, 1
• Administer aspirin 75–100 mg orally or intravenously immediately unless active bleeding or severe allergy is present 2, 1
• Initiate continuous cardiac monitoring with defibrillator capability at the bedside to detect life-threatening arrhythmias 2, 1
• Avoid routine supplemental oxygen unless peripheral oxygen saturation is <90%; routine oxygen does not improve outcomes and may cause harm 2, 1

Reperfusion Strategy Selection

Primary PCI (Preferred Method)

• Transfer directly to the cardiac catheterization laboratory, bypassing the emergency department and ICU, to minimize door-to-balloon time 2, 1
• Activate the catheterization laboratory immediately upon STEMI diagnosis; PCI-capable centers must provide 24/7 service 1
• Administer a potent P2Y12 inhibitor before or at the time of PCI: ticagrelor preferred (180 mg loading dose); prasugrel (60 mg loading dose) is an alternative but contraindicated in patients ≥75 years with prior stroke/TIA; clopidogrel (600 mg loading dose) only if the former are unavailable 2, 1
• Use unfractionated heparin (70–100 units/kg bolus, target ACT 250–350 seconds) or enoxaparin (0.5 mg/kg IV bolus) for intraprocedural anticoagulation 2, 1
• Fondaparinux is absolutely contraindicated for primary PCI due to catheter-thrombosis risk 2, 1
• Use radial arterial access as the standard approach to minimize bleeding complications 1

Fibrinolytic Therapy (When Primary PCI Cannot Be Performed Within 120 Minutes)

• Administer fibrinolytic therapy within 12 hours of symptom onset if primary PCI cannot be achieved within 120 minutes of STEMI diagnosis and no contraindications exist 2, 1
• Select a fibrin-specific agent: tenecteplase (weight-based single bolus), alteplase, or reteplase 2, 1
• Add clopidogrel 300 mg loading dose (75 mg if age >75 years) to aspirin for dual antiplatelet therapy 2, 1
• Use enoxaparin (30 mg IV bolus followed by 1 mg/kg subcutaneous every 12 hours) for anticoagulation; weight-adjusted unfractionated heparin (60 units/kg bolus, maximum 4000 units, then 12 units/kg/hour infusion, maximum 1000 units/hour, target aPTT 50–70 seconds) is an acceptable alternative 2, 1
• Arrange immediate transfer to a PCI-capable center after fibrinolysis for all patients 2, 1
• Schedule angiography and PCI of the infarct-related artery between 2 and 24 hours post-therapy in stable patients after successful fibrinolysis 2, 1
• Perform emergency angiography and PCI without delay if the patient develops heart failure, cardiogenic shock, hemodynamic instability, or electrical instability 2, 1
• Initiate rescue PCI immediately if fibrinolysis fails (≤50% ST-segment resolution at 60–90 minutes) 2, 1

Unit Assignment and Monitoring

• Admit patients with ongoing angina, hemodynamic instability, uncontrolled arrhythmias, large MI with heart failure, or cardiogenic shock to a cardiac intensive care unit (CICU) 2
• Stable patients without recurrent ischemia, significant arrhythmias, pulmonary edema, or hemodynamic instability can be admitted to an intermediate care or telemetry unit 2
• Ensure continuous electrocardiographic rhythm monitoring, frequent vital sign assessment, and immediate defibrillation capability with appropriate nurse-to-patient ratios 2
• Monitor patients for at least 24 hours after reperfusion therapy in a coronary care or intensive care unit setting 1

Adjunctive Pharmacotherapy (Within 24 Hours)

Cardioprotective Medications

• Initiate high-intensity statin therapy immediately: atorvastatin 80 mg daily or rosuvastatin 40 mg daily, targeting LDL-C <1.8 mmol/L (≈70 mg/dL) or ≥50% reduction 2, 1
• Start an ACE inhibitor within the first 24 hours in patients with heart failure, LVEF <40%, diabetes, or anterior infarction; use an ARB (e.g., valsartan 40–80 mg twice daily) for ACE-intolerant patients 2, 1
• Begin oral beta-blocker therapy in patients with heart failure and/or LVEF <40% unless contraindicated: metoprolol tartrate 25–50 mg twice daily or carvedilol 3.125–6.25 mg twice daily, titrating upward 2, 1
• Do NOT administer intravenous beta-blockers in patients with hypotension, acute heart failure, high-grade AV block, or severe bradycardia 2, 1
• Add a mineralocorticoid-receptor antagonist (eplerenone 25 mg daily or spironolactone 12.5–25 mg daily) in patients with LVEF <40% and heart failure or diabetes who are already on ACE-inhibitor and beta-blocker, provided eGFR >30 mL/min/1.73 m² and potassium <5.0 mEq/L 1

Antiplatelet and Anticoagulation Maintenance

• Continue dual antiplatelet therapy (aspirin 75–100 mg daily + ticagrelor 90 mg twice daily or prasugrel 10 mg daily) for 12 months unless bleeding risk is excessive 2, 1
• Add a proton-pump inhibitor (omeprazole 20 mg daily or pantoprazole 40 mg daily) in patients at high risk of gastrointestinal bleeding 1
• Continue anticoagulation until revascularization or for the duration of the hospital stay, up to 8 days 1

Analgesia

• Use intravenous morphine cautiously (2–4 mg IV every 5–15 minutes as needed); observational data show higher rates of death (5.5% vs 4.7%), myocardial infarction (3.8% vs 3.0%), and the composite of death/MI (8.5% vs 7.1%) compared with no morphine 1

Anemia Management

• In patients with acute or chronic anemia, blood transfusion to achieve a hemoglobin level ≥10 g/dL may be reasonable to reduce cardiovascular events, though observational studies associate transfusion with worse outcomes and randomized trials in other populations favor restrictive strategies (targeting hemoglobin ≈8 g/dL) 2

Early In-Hospital Assessment

• Perform routine transthoracic echocardiography during the hospital stay to assess left- and right-ventricular function, detect early mechanical complications (ventricular septal defect, papillary-muscle rupture, free-wall rupture), and exclude left-ventricular thrombus 2, 1

Secondary Prevention Initiated During Hospitalization

• Identify all smokers and provide repeated cessation counseling with pharmacotherapy (varenicline, bupropion, or nicotine-replacement therapy) and behavioral support 1
• Enroll every patient in a structured cardiac rehabilitation program before discharge 1

Critical Pitfalls to Avoid

• Do NOT postpone reperfusion therapy for routine echocardiography or other non-essential testing in clear STEMI cases 1
• Do NOT perform routine PCI of an occluded infarct-related artery beyond 48 hours after STEMI onset in asymptomatic patients 2, 1
• Do NOT use fondaparinux as anticoagulation for primary PCI 2, 1
• Do NOT use glucocorticoids or nonsteroidal anti-inflammatory drugs (other than aspirin) due to possible increased risk of recurrent MI, impaired myocardial healing, and risk of rupture 2

Evidence Supporting Standardized Order Sets

The use of standardized electronic order sets for acute MI is associated with a 50% increase in patients receiving ≥5 evidence-based therapies (50% vs 36% with individual orders), lower 30-day mortality (5.7% vs 8.5%), and a 33% reduction in inpatient mortality after risk adjustment (relative risk 0.67,95% CI 0.52–0.86). 3 Standardized admission orders improve hospital performance on process-of-care measures including timely fibrinolysis (≤30 minutes), primary PCI (≤90 minutes), aspirin administration (≤6 hours), and lipid testing (≤24 hours), though they do not independently reduce mortality unless they improve adherence to evidence-based therapies 4. Patients who receive ≥3 evidence-based therapies have 50% lower odds of 30-day mortality, and the benefit of standardized orders is mediated entirely through increased adherence to guideline-directed treatment 3, 4.